


Bedford Massachusetts Drug Delivery Company Integral BioSystems Announces China's Patent Grant on OcuSurf™ Innovation

Specialty drug delivery company Integral BioSystems LLC has won a broad patent allowance from the CNIPA for its platform delivery innovation OcuSurf™



BEDFORD, MASSACHUSETTS, US,
March 8, 2019 /EINPresswire.com/ --
Bedford, MA-based [Integral](#)

[BioSystems](#) has won a patent

allowance from the China National Intellectual Property Administration (CNIPA) for one of its flagship inventions, OcuSurf™, a novel, patented, differentiated and improved membrane-mimetic delivery system for medications to treat disorders of the ocular surface and the anterior chamber of the eye. Due to the high tissue permeation enabled by OcuSurf™, this innovation is

an excellent 505b2 strategy to generate products that have a superior product profile to the branded medication.

Alternatively, the innovation can also be utilized as a product extension strategy for patent-expired products or to offer a path to render insoluble, impermeable drugs bioavailable.



OcuSurf™ can improve the effectiveness of many drug substances"

Dr. Shikha Barman

Products formulated in OcuSurf™ are highly bioavailable,

membrane-mimetic and tissue-permeating, due to its ability to rapidly absorb into tissue. Integral BioSystems is developing an ophthalmic pipeline utilizing this technology, including glaucoma, dry eye and blepharitis. As a business strategy, Integral invites licensing-based collaborations for other potential applications in ophthalmic, dermal or other routes that can benefit from this technology.

The Details

A substantial number of ophthalmic drug products for disorders of the ocular surface are hydrophobic, or sparingly soluble in water, and formulated as suspensions. This results in less than 5% of each eye-drop actually being absorbed by the target tissue. Such formulations typically contain a high concentration of drug to achieve a therapeutic effect. OcuSurf™ nanostructured emulsions are formulated into mucosa-penetrating, tissue absorbed nanoparticles, melting at body temperature to release dissolved drug at the requisite tissue site, allowing much less drug to be administered for equivalent or better therapeutic effect.

Integral BioSystems is developing an ophthalmic pipeline utilizing this technology. As a business strategy, Integral invites licensing-based collaborations for other potential applications in ophthalmic, dermal or other routes that can benefit from this technology.

About Integral BioSystems

Since its formation in 2011, Integral BioSystems has established credibility in drug formulation, CMC consulting, analytical method development and methods qualification, as well as scale-up process engineering. Along with its strong presence as an ophthalmic product development CRO,

the company also has expertise in other routes, including injectables, infusions, topical dermal gels/creams, and nanocrystals. Integral BioSystems provides expertise and know-how in developing both front-of-the-eye and back-of-the-eye products, offering complete development services in pre-formulation, including bioanalytical.

For companies seeking to develop a new product that is using a re-purposed drug, Integral offers its innovative delivery systems as licensable technologies to build value into prospective clients' drug products through a 505b2 regulatory strategy. For companies seeking product life cycle management, Integral can help them quickly ascertain if Integral's innovations can provide the desired improvements. With multiple billion dollar drug products going off-patent, this presents a cost effective way to develop an extended product life cycle with novel IP. In this manner, Integral will offer its insight and technological innovations in drug delivery to strategize and improve the customer's product portfolio.

Dave Karasic
Integral BioSystems, LLC
+1 617-820-8483
[email us here](#)

This press release can be viewed online at: <http://www.einpresswire.com>

Disclaimer: If you have any questions regarding information in this press release please contact the company listed in the press release. Please do not contact EIN Presswire. We will be unable to assist you with your inquiry. EIN Presswire disclaims any content contained in these releases. © 1995-2020 IPD Group, Inc. All Right Reserved.